Related Experiment Video

Updated: May 20, 2026

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch

Igor N Petrovic1, Helen Ling, Yasmine Asi

  • 1National Hospital for Neurology and Neurosurgery, Queen Square, and the Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom.

Movement Disorders : Official Journal of the Movement Disorder Society
|July 19, 2012
PubMed
Abstract

Insights

Multiple system atrophy (MSA), a neurodegenerative disease, can have a prolonged course. Late-onset dysautonomia in MSA-P patients indicates a favorable prognosis, suggesting a distinct clinical subgroup.

Area of Science:

  • Neurology
  • Neurodegenerative Diseases

Background:

  • Multiple system atrophy (MSA) is a severe neurodegenerative disorder.
  • Typical disease duration ranges from 6 to 9 years.

Purpose of the Study:

  • To analyze clinical and neuropathological features of MSA cases with extended disease duration (≥15 years).
  • To identify prognostic factors in MSA, particularly the timing of dysautonomia onset.

Main Methods:

  • Retrospective analysis of 4 patients with long-standing MSA.
  • Detailed examination of clinical symptoms, disease progression, and response to treatment.

Main Results:

  • All analyzed patients exhibited parkinsonism.
  • A significant delay (mean 11 years) was observed between initial symptoms and the development of dysautonomia.
  • Symptoms like anterocollis, inspiratory stridor, and dysphagia appeared after a mean of 9 years.
  • Levodopa treatment showed limited efficacy but induced dyskinesia in all patients.

Conclusions:

  • Late onset of dysautonomia is a positive prognostic indicator in MSA with parkinsonism (MSA-P).
  • Recognition of this uncommon, "benign" MSA subgroup can enhance diagnostic accuracy.
  • Improved understanding aids in more precise treatment strategies for these patients.

More Related Videos

A Gravity-Fed Transcardial Perfusion Method for Histologic Analysis of the Mouse Central Nervous System10:37

A Gravity-Fed Transcardial Perfusion Method for Histologic Analysis of the Mouse Central Nervous System

Published on: January 21, 2022

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...